Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "De-Novo-pathway"

2 News Found

Essilor Stellest lens positioned as key breakthrough in myopia control in India
News | April 28, 2026

Essilor Stellest lens positioned as key breakthrough in myopia control in India

The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025

EssilorLuxottica receives FDA authorization for its Essilor Stellest lens for myopia control
Medical Device | April 28, 2026

EssilorLuxottica receives FDA authorization for its Essilor Stellest lens for myopia control

The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

India’s pharma market to hit US$ 130 billion, exports US$ 80 billion by 2030: ASSOCHAM

Biopharma SHAKTI envisages launch of 100 biologics by 2047: Anupriya Patel

Major UK study to evaluate newborn screening for spinal muscular atrophy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech
Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences
Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences
Dr. Ramesh Hariharan Chief Executive Officer, Strand Life Sciences

Packaging